Explore

Trendline Trendline
Zegna to Host Major Runway Show in Los Angeles Amid Luxury Market Expansion

Zegna to Host Major Runway Show in Los Angeles Amid Luxury Market Expansion

Zegna to Host Major Runway Show in Los Angeles Amid Luxury Market Expansion
Trendline Trendline
Akeso's VEGF/PD-1 Therapy Shows Promise in Lung Cancer Survival

Akeso's VEGF/PD-1 Therapy Shows Promise in Lung Cancer Survival

Akeso's VEGF/PD-1 Therapy Shows Promise in Lung Cancer Survival
Rapid Read Rapid Read
Innovent's IBI363 Shows Promising Survival Benefits in Immunotherapy-Resistant Lung Cancer

Innovent's IBI363 Shows Promising Survival Benefits in Immunotherapy-Resistant Lung Cancer

Innovent Biologics has announced promising results from a Phase 1 proof-of-concept clinical study of its PD-1/IL-2α-bias bispecific fusion protein, IBI363, in treating advanced immunotherapy-resistant non-small cell lung cancer (NSCLC). The study, presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, involved 136 subjects with NSCLC who received IBI363 monotherapy. The results showed significant survival benefits, particularly in patients with squamous NSCLC and those with a smoking history. The median overall survival (OS) for patients in the 3 mg/kg dose group reached 18.2 months for squamous NSCLC and 15.2 months for adenoNSCLC. The study also highlighted a favorable safety profile for IBI363, with manageable adverse events.
Trendline Trendline
Korean Beauty Giant Olive Young Opens First U.S. Store in Pasadena

Korean Beauty Giant Olive Young Opens First U.S. Store in Pasadena

Korean Beauty Giant Olive Young Opens First U.S. Store in Pasadena
Rapid Read Rapid Read
FDA Grants Breakthrough Therapy Designation to Calderasib for KRAS G12C-Mutant NSCLC Patients

FDA Grants Breakthrough Therapy Designation to Calderasib for KRAS G12C-Mutant NSCLC Patients

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to calderasib (MK-1084), an investigational KRAS G12C inhibitor developed by Merck, for the treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC) with KRAS G12C mutation and PD-L1 expression. This designation is based on positive data from the Phase 1 KANDLELIT-001 trial. Calderasib is being developed in collaboration with Taiho Pharmaceutical Co. Ltd. and Astex Pharmaceuticals. The Breakthrough Therapy designation aims to expedite the development and review of drugs that show substantial improvement over existing therapies for serious conditions.
Reuters Reuters
J&J prostate cancer drug reduces risk of cancer spread and death in late-stage study

J&J prostate cancer drug reduces risk of cancer spread and death in late-stage study

By Sneha S K May 31 (Reuters) - Johnson & Johnson's prostate cancer drug Erleada used with hormone-blocking therapy six months before and after prostate surgery improved the chances of eliminating the cancer and reduced the risk of disease progression or death, according to data from a late-stage
Rapid Read Rapid Read
MannKind Corporation Secures FDA Approval for Afrezza Inhaled Insulin for Children with Diabetes

MannKind Corporation Secures FDA Approval for Afrezza Inhaled Insulin for Children with Diabetes

MannKind Corporation has announced that the U.S. Food and Drug Administration (FDA) has approved Afrezza, an inhaled insulin, for use in children and adolescents aged 6 and older with type 1 and type 2 diabetes. This approval marks a significant advancement in pediatric diabetes care, offering a new mealtime insulin option that is needle-free. Afrezza is administered at the beginning of meals using a small, portable inhaler, allowing for rapid absorption through the lungs. This method closely mimics the body's natural insulin response to meals. The approval is supported by the results of the Phase 3 INHALE-1 study and additional clinical data collected over two decades. Afrezza is now available for eligible patients at a cost of $35 or less per month, with support provided through MannKind Cares.
Trendline Trendline
Juiced Bikes Launches New Electric Mopeds in the U.S., Marking a Major Product Relaunch

Juiced Bikes Launches New Electric Mopeds in the U.S., Marking a Major Product Relaunch

Juiced Bikes Launches New Electric Mopeds in the U.S., Marking a Major Product Relaunch
Trendline Trendline
CVS Health Wins AI Impact Award for Enhancing Medication Safety

CVS Health Wins AI Impact Award for Enhancing Medication Safety

CVS Health Wins AI Impact Award for Enhancing Medication Safety
Rapid Read Rapid Read
FDA Grants Breakthrough Therapy Designation to Calderasib for KRAS G12C-Mutant Lung Cancer

FDA Grants Breakthrough Therapy Designation to Calderasib for KRAS G12C-Mutant Lung Cancer

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to calderasib (MK-1084), an investigational KRAS G12C inhibitor, for the first-line treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC) with KRAS G12C-mutation and expressing PD-L1. This designation is based on positive data from the Phase 1 KANDLELIT-001 trial. Calderasib, developed by Merck, is a next-generation KRAS G12C covalent inhibitor, targeting a mutation found in approximately 14% of NSCLC patients. The FDA's Breakthrough Therapy designation aims to expedite the development and review of drugs that show substantial improvement over existing therapies for serious conditions.
Trendline Trendline
Stella Artois Launches World Cup Campaign with David Beckham

Stella Artois Launches World Cup Campaign with David Beckham

Stella Artois Launches World Cup Campaign with David Beckham
Trendline Trendline
Olive Young Opens First U.S. Store in Pasadena, Expanding K-Beauty Presence

Olive Young Opens First U.S. Store in Pasadena, Expanding K-Beauty Presence

Olive Young Opens First U.S. Store in Pasadena, Expanding K-Beauty Presence